A newly identified molecule made exclusively by gut bacteria can worsen primary sclerosing cholangitis (PSC), a serious liver and bile duct disease. Researchers at the University of Oslo and Oslo University Hospital, along with international collaborators, have shown that this bacterial molecule actively drives inflammation and scarring in the bile ducts. The finding, reported in a peer-reviewed journal, could lead to new treatments that target the gut microbiome to slow or prevent disease progression.

Key Takeaways

  • A specific molecule made by gut bacteria directly contributes to bile duct damage in primary sclerosing cholangitis (PSC).
  • The discovery came from an international team led by the University of Oslo and Oslo University Hospital.
  • This molecule may serve as a new target for therapies that modify the gut microbiome.
  • PSC is a chronic condition that often leads to liver failure and currently has no approved drug treatments.

Understanding Primary Sclerosing Cholangitis

Primary sclerosing cholangitis is a chronic disease in which the bile ducts inside and outside the liver become inflamed, scarred, and eventually blocked. Bile, a fluid that helps digest fats, builds up in the liver and causes damage. Over time, this leads to cirrhosis, liver failure, and an increased risk of bile duct cancer. PSC affects about 1 in 10,000 people and is more common in men. The cause has been unclear, but many patients also have inflammatory bowel disease, suggesting a link to gut health.

The Role of Gut Bacteria in PSC

Scientists have long suspected that the gut microbiome, the community of bacteria living in the intestines, plays a role in PSC. In the new study, researchers focused on a small molecule that only gut bacteria can produce. They found that this molecule can travel from the gut to the liver and bile ducts, where it triggers an immune response that worsens inflammation and fibrosis, or scarring. The molecule appears to be a metabolite that is normally harmless in healthy people but becomes problematic in those with PSC.

How the Bacterial Molecule Harms Bile Ducts

The team used laboratory models and human tissue samples to trace the molecule’s effects. Once inside the bile ducts, the bacterial molecule activated immune cells called macrophages, which released inflammatory signals. These signals attracted more immune cells and stimulated the cells lining the bile ducts to produce excess collagen, a key component of scar tissue. The researchers also found that levels of this molecule were higher in PSC patients compared to healthy controls, and that higher levels correlated with more severe disease.

Importantly, the molecule is not produced by human cells. It is made by a specific group of gut bacteria, including some that are more abundant in people with PSC. This suggests that altering the composition of the gut microbiome, or blocking the molecule itself, could reduce bile duct damage.

Implications for Treatment and Prevention

Currently, no medications are approved to slow or stop PSC. Liver transplantation is the only option for advanced disease, but the condition can recur in the new liver. The discovery of this gut-derived molecule opens the door to new approaches. Potential strategies include using antibiotics to reduce the bacteria that produce the molecule, developing drugs that block the molecule from reaching the liver, or using probiotics to crowd out harmful bacteria.

The researchers caution that the work is still in the early stages. More studies are needed to confirm the molecule’s role in a larger group of patients and to test whether targeting it can safely improve outcomes. However, the findings provide a clear biological target that was not previously known, and they highlight the close connection between gut health and liver disease.

Frequently Asked Questions

What is primary sclerosing cholangitis?

Primary sclerosing cholangitis (PSC) is a chronic liver disease where the bile ducts become inflamed and scarred, leading to bile buildup, liver damage, and eventually cirrhosis or liver failure. Many patients also have inflammatory bowel disease, but the exact cause remains unknown.

How does gut bacteria contribute to PSC?

In this study, researchers found that a molecule produced only by certain gut bacteria can travel to the bile ducts and trigger inflammation and scarring. This suggests that the gut microbiome plays a direct role in driving the disease, rather than just being a bystander.

Could this discovery lead to a new treatment?

Yes, the molecule represents a new target for therapy. Future treatments might include drugs that block the molecule, antibiotics that reduce the responsible bacteria, or probiotics that restore a healthy microbiome. However, these approaches are still being researched and are not yet available for patients.

This is an original report by Vital Signs Today, informed by reporting from Medical Xpress. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.